Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Acta Biomater. 2018 Jun 22;76:193–207. doi: 10.1016/j.actbio.2018.06.029

Fig. 7.

Fig. 7.

Anti-tumor therapeutic efficacy of nano-vaccines. (A) Therapeutic assay schedule, (B) Body weight over time, (C) Tumor growth curve and representative tumor images of each treated group on day 18, (D) Tumor mass per 100 g of final body weight on day 18, Mean percentage of (E) NK (CD45+CD3-NK1.1+) cells, (F) NKT (CD45+CD3+NK1.1+) cells and (G) CD4+ (CD45+CD3+CD4+) and CD8+ (CD45+CD3+CD8+) T cells at day 18 obtained by flow cytometry. Mean ± SD; n = 6, where n stands for number of measurements per experiment. Statistics: Independent samples t-test; *p < 0.05, **p < 0.01 and ***p < 0.001.